You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Alafair Biosciences develops cross-linked polysaccharide hydrogel films to addres

    SBC: ALAFAIR BIOSCIENCES, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): The goal of this STTR project is to develop a pre-formed, naturally-based hydrogel postoperative adhesion barrier with improved handling characteristics, laparoscopic deliverability, and consistent efficacy. Our technology is based on a novel, patented process that imparts exceptional elasticity and toughness on normally brittle, weak materials. Postoperative a ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Neurorestorative therapy of stroke with HUCBC in T2DM rats

    SBC: SANERON CCEL THERAPEUTICS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): Diabetes mellitus (DM) leads to a 3-4 fold higher risk of experiencing ischemic stroke. In addition, DM stroke patients are more prone to develop more and earlier white matter (WM) high-intensity lesions than non DM stroke patients. Treatment of stroke with tissue plasminogen activator (rtPA) at 2-3 hours after stroke decreases lesion volume in non-DM rats. How ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Conversations About Cancer (CAC): A Theatrical Production

    SBC: KLEIN BUENDEL, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Over the past decade, an investigation of how family members talk through cancer on the telephone has resulted in the recent publication of a lengthy volume entitled A Natural History of Family Cancer: Interactional Resources for Managing Illness (NH). Based on the conversations analyzed for this volume, and related research on the psychosocial impacts and con ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  4. Pharmacologic Suppression of Reperfusion Injury Following Endovascular Thrombectomy In Stroke.

    SBC: BIOMIMETIX JV LLC            Topic: 102

    Ischemic stroke is a leading cause of death and disability in the United States. This often is attributable to thrombus formation at an atherosclerotic plaque or thromboembolism. Patients who present within 4.5 hours of symptom onset are eligible for thrombolysis with tissue plasminogen activator (tPA). This serves andlt;5% of victims. Recently, major advance has been made with proven efficacy fro ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Cotton Rat: Animal Model Predictive of Clinical Responses to HSV Vaccines

    SBC: VIRION SYSTEMS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Genital herpes is one of the most prevalent sexually transmitted infections worldwide and is associated with substantial morbidity. The impact of genital herpes as a public health threat is amplified because of its epidemiologic synergy with HIV. Epidemiological studies consistently demonstrate that HSV infection increases the risk of HIV transmission and acqu ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  6. A Synthetic Human Cytomegalovirus Vaccine Platform

    SBC: TOMEGAVAX, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The goal of this project is to synthesize, based on genomic sequence information, a human cytomegalovirus (HCMV) strain with demonstrated ability to establish persistent infection in sero-positive individuals. The resulting synthetic product will form the basis for the development of attenuated HCMV vaccines. Innovative synthetic biology methods will overcome ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Humanized Monoclonal Antibodies to Treat Acinetobacter Infections

    SBC: BIOLOGICAL ANTI-INFECTIVE MEDICINES, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): In the last decade, Acinetobacter baumannii has emerged as one of the most highly antibiotic-resistant pathogens in the United States (US) and throughout the world. These infections are increasingly prevalent and highlylethal, killing 50-60% of those infected. Worse, strains of A. baumannii that no known antibiotic will kill have now emerged, and will continue ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Mitochondrial Dysfunction in HAART: Point of Care Tests

    SBC: MITOSCIENCES, INC            Topic: NIGMS

    DESCRIPTION (provided by applicant): Highly Active Anti-Retroviral Therapy (HAART) used to treat HIV/AIDS has serious side-effects, including metabolic complications from mitochondrial toxicities that can be life-threatening, and limit effectiveness and patient compliance. Adverse metabolic effects are now managed by adept clinicians who monitor patients closely for clinical symptoms and adjust t ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  9. Immunotherapeutics to prevent HCV reinfection

    SBC: Integrated Biotherapeutics, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Up to 170 million people worldwide are chronically infected with HCV Hepatitis C virus (HCV) putting the infected individuals at significant risk for cirrhosis, liver failure and liver cancer. End- stage liver diseasecaused by HCV is the leading indication of liver transplantation (LT) in the United States. However, reinfection with HCV occurs universally and ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Monoclonal antibodies targeting novel sites of vulnerability in marburg virus glycoprotein

    SBC: Integrated Biotherapeutics, Inc.            Topic: NIAID

    Filoviruses, consisting of two major virus families including the ebolaviruses and marburgviruses (MARV and RAVV), cause periodic outbreaks of severe viral hemorrhagic fever with mortality rates as high as 90%. Since it is difficult to predict the species that would dominate future outbreaks, development of broadly protective therapeutics to prevent and manage future filovirus outbreaks is of high ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government